Study backs Nymox's urine test for Alzheimer's:
This article was originally published in Clinica
Nymox says that a double-blind, 139-participant, US study of its AlzheimAlert urine test for Alzheimer's disease has provided further evidence to validate the product. The test, which is already available in the US, identifies a brain protein (neural thread protein) known to be elevated in Alzheimer's patients. The new study, to be published in an upcoming issue of Alzheimer's Reports, also underlined the test's potential for monitoring disease progression and response to treatment, after higher levels of the protein were found in later stage Alzheimer's cases than earlier stage cases, says the Maywood, New Jersey firm.